Literature DB >> 27404185

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Alison J Rodger1, Valentina Cambiano1, Tina Bruun2, Pietro Vernazza3, Simon Collins4, Jan van Lunzen5, Giulio Maria Corbelli6, Vicente Estrada7, Anna Maria Geretti8, Apostolos Beloukas8, David Asboe9, Pompeyo Viciana10, Félix Gutiérrez11, Bonaventura Clotet12, Christian Pradier13, Jan Gerstoft14, Rainer Weber15, Katarina Westling16, Gilles Wandeler17, Jan M Prins18, Armin Rieger19, Marcel Stoeckle20, Tim Kümmerle21, Teresa Bini22, Adriana Ammassari23, Richard Gilson1, Ivanka Krznaric24, Matti Ristola25, Robert Zangerle26, Pia Handberg27, Antonio Antela28, Sris Allan29, Andrew N Phillips1, Jens Lundgren2.   

Abstract

IMPORTANCE: A key factor in assessing the effectiveness and cost-effectiveness of antiretroviral therapy (ART) as a prevention strategy is the absolute risk of HIV transmission through condomless sex with suppressed HIV-1 RNA viral load for both anal and vaginal sex.
OBJECTIVE: To evaluate the rate of within-couple HIV transmission (heterosexual and men who have sex with men [MSM]) during periods of sex without condoms and when the HIV-positive partner had HIV-1 RNA load less than 200 copies/mL. DESIGN, SETTING, AND PARTICIPANTS: The prospective, observational PARTNER (Partners of People on ART-A New Evaluation of the Risks) study was conducted at 75 clinical sites in 14 European countries and enrolled 1166 HIV serodifferent couples (HIV-positive partner taking suppressive ART) who reported condomless sex (September 2010 to May 2014). Eligibility criteria for inclusion of couple-years of follow-up were condomless sex and HIV-1 RNA load less than 200 copies/mL. Anonymized phylogenetic analysis compared couples' HIV-1 polymerase and envelope sequences if an HIV-negative partner became infected to determine phylogenetically linked transmissions. EXPOSURES: Condomless sexual activity with an HIV-positive partner taking virally suppressive ART. MAIN OUTCOMES AND MEASURES: Risk of within-couple HIV transmission to the HIV-negative partner.
RESULTS: Among 1166 enrolled couples, 888 (mean age, 42 years [IQR, 35-48]; 548 heterosexual [61.7%] and 340 MSM [38.3%]) provided 1238 eligible couple-years of follow-up (median follow-up, 1.3 years [IQR, 0.8-2.0]). At baseline, couples reported condomless sex for a median of 2 years (IQR, 0.5-6.3). Condomless sex with other partners was reported by 108 HIV-negative MSM (33%) and 21 heterosexuals (4%). During follow-up, couples reported condomless sex a median of 37 times per year (IQR, 15-71), with MSM couples reporting approximately 22,000 condomless sex acts and heterosexuals approximately 36,000. Although 11 HIV-negative partners became HIV-positive (10 MSM; 1 heterosexual; 8 reported condomless sex with other partners), no phylogenetically linked transmissions occurred over eligible couple-years of follow-up, giving a rate of within-couple HIV transmission of zero, with an upper 95% confidence limit of 0.30/100 couple-years of follow-up. The upper 95% confidence limit for condomless anal sex was 0.71 per 100 couple-years of follow-up. CONCLUSIONS AND RELEVANCE: Among serodifferent heterosexual and MSM couples in which the HIV-positive partner was using suppressive ART and who reported condomless sex, during median follow-up of 1.3 years per couple, there were no documented cases of within-couple HIV transmission (upper 95% confidence limit, 0.30/100 couple-years of follow-up). Additional longer-term follow-up is necessary to provide more precise estimates of risk.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27404185     DOI: 10.1001/jama.2016.5148

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  408 in total

1.  The Unanticipated Benefits of PrEP for Young Black Gay, Bisexual, and Other Men Who Have Sex with Men.

Authors:  Katherine G Quinn; Erika Christenson; Mark T Sawkin; Elizabeth Hacker; Jennifer L Walsh
Journal:  AIDS Behav       Date:  2020-05

Review 2.  Recent mobile health interventions to support medication adherence among HIV-positive MSM.

Authors:  Kathryn E Muessig; Sara LeGrand; Keith J Horvath; José A Bauermeister; Lisa B Hightow-Weidman
Journal:  Curr Opin HIV AIDS       Date:  2017-09       Impact factor: 4.283

3.  Towards a cure for human immunodeficiency virus.

Authors:  Matthew C Pitman; Sharon R Lewin
Journal:  Intern Med J       Date:  2018-01       Impact factor: 2.048

4.  Disparities in HIV Viral Load Suppression by Race/Ethnicity Among Men Who Have Sex with Men in the HIV Outpatient Study.

Authors:  Kate Buchacz; Carl Armon; Ellen Tedaldi; Frank J Palella; Richard M Novak; Douglas Ward; Rachel Hart; Marcus D Durham; John T Brooks
Journal:  AIDS Res Hum Retroviruses       Date:  2018-02-13       Impact factor: 2.205

5.  Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention.

Authors:  Mina Psichogiou; George Giallouros; Katerina Pantavou; Eirini Pavlitina; Martha Papadopoulou; Leslie D Williams; Andria Hadjikou; Eleni Kakalou; Athanasios Skoutelis; Konstantinos Protopapas; Anastasia Antoniadou; George Boulmetis; Dimitrios Paraskevis; Angelos Hatzakis; Samuel R Friedman; Georgios K Nikolopoulos
Journal:  AIDS Care       Date:  2019-04-02

6.  Simulating the End of AIDS in New York: Using Participatory Dynamic Modeling to Improve Implementation of the Ending the Epidemic Initiative.

Authors:  Erika G Martin; Roderick H MacDonald; Daniel E Gordon; Carol-Ann Swain; Travis O'Donnell; John Helmeset; Adenantera Dwicaksono; James M Tesoriero
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

7.  90-90-90-Plus: Maintaining Adherence to Antiretroviral Therapies.

Authors:  Inge B Corless; Alex J Hoyt; Lynda Tyer-Viola; Elizabeth Sefcik; Jeanne Kemppainen; William L Holzemer; Lucille Sanzero Eller; Kathleen Nokes; J Craig Phillips; Carol Dawson-Rose; Marta Rivero-Mendez; Scholastika Iipinge; Puangtip Chaiphibalsarisdi; Carmen J Portillo; Wei-Ti Chen; Allison R Webel; John Brion; Mallory O Johnson; Joachim Voss; Mary Jane Hamilton; Kathleen M Sullivan; Kenn M Kirksey; Patrice K Nicholas
Journal:  AIDS Patient Care STDS       Date:  2017-05       Impact factor: 5.078

8.  Dolutegravir in pregnancy-effects on HIV-positive women and their infants.

Authors:  Riikka Bornhede; Sandra Soeria-Atmadja; Katarina Westling; Karin Pettersson; Lars Navér
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-02-02       Impact factor: 3.267

9.  Using HIV Surveillance Data to Link People to HIV Medical Care, 5 US States, 2012-2015.

Authors:  John Beltrami; Odessa Dubose; Reginald Carson; Janet C Cleveland
Journal:  Public Health Rep       Date:  2018-05-11       Impact factor: 2.792

10.  HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015: A Cohort Study.

Authors:  Robin M Nance; J A Chris Delaney; Jane M Simoni; Ira B Wilson; Kenneth H Mayer; Bridget M Whitney; Frances M Aunon; Steven A Safren; Michael J Mugavero; W Christopher Mathews; Katerina A Christopoulos; Joseph J Eron; Sonia Napravnik; Richard D Moore; Benigno Rodriguez; Bryan Lau; Rob J Fredericksen; Michael S Saag; Mari M Kitahata; Heidi M Crane
Journal:  Ann Intern Med       Date:  2018-08-21       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.